Printer manufacturer Seiko Instruments has released a new lineof dye sublimation printers that add support for the PostScriptprinting protocol. Seiko hopes that the 8.5 x 11 version of theprinter line will help solidify its position in the nuclear
Printer manufacturer Seiko Instruments has released a new lineof dye sublimation printers that add support for the PostScriptprinting protocol. Seiko hopes that the 8.5 x 11 version of theprinter line will help solidify its position in the nuclear medicinemarket, where it holds a 56% market share for 8.5 x 11 printers,according to the firm.
The new printers are ColorPoint 820 PS for 8.5 x 11 printsand ColorPoint 830 PS for 11 x 17 images. The printers have anAdobe PostScript Level 2 interpreter embedded in them that enablesthem to support PostScript, according to Craig Lynar, directorof marketing for Seiko's color graphics group in San Jose, CA.
Many medical imaging vendors now format their images in PostScriptdue to the image quality advantages the protocol confers overstandard screen-capture video, Lynar said. Seiko plans to adda DICOM-compatible version to the line later this year. Seikowill continue to offer its Professional ColorPoint 2 VSF printerfor video-capture printing (SCAN 3/16/94).
Both new printers output at 300 dpi and support thermal waxtransfer printing as well as dye sublimation. Cost per letter-sizeprint is 50¢ in thermal wax mode and $2.30 in the higherresolution dye sublimation mode. Seiko has added seven new imagesmoothing algorithms to the printers to remove pixelation artifactsand make images easier to read.
Seiko will target the printers at the nuclear medicine, radiationtherapy, MRI, and CT markets. In nuclear medicine, Seiko's OEMpartners include GE, Siemens, ADAC, Toshiba, and Elscint. ColorPoint820 PS will carry a list price of $7999 while ColorPoint 830 PSis listed at $14,999.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.